These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 35821637)

  • 1. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells.
    Bevers S; Kooijmans SAA; Van de Velde E; Evers MJW; Seghers S; Gitz-Francois JJJM; van Kronenburg NCH; Fens MHAM; Mastrobattista E; Hassler L; Sork H; Lehto T; Ahmed KE; El Andaloussi S; Fiedler K; Breckpot K; Maes M; Van Hoorick D; Bastogne T; Schiffelers RM; De Koker S
    Mol Ther; 2022 Sep; 30(9):3078-3094. PubMed ID: 35821637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines.
    Han X; Alameh MG; Butowska K; Knox JJ; Lundgreen K; Ghattas M; Gong N; Xue L; Xu Y; Lavertu M; Bates P; Xu J; Nie G; Zhong Y; Weissman D; Mitchell MJ
    Nat Nanotechnol; 2023 Sep; 18(9):1105-1114. PubMed ID: 37365276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Throughput
    Hamilton AG; Swingle KL; Thatte AS; Mukalel AJ; Safford HC; Billingsley MM; El-Mayta RD; Han X; Nachod BE; Joseph RA; Metzloff AE; Mitchell MJ
    ACS Nano; 2024 Jun; 18(25):16151-16165. PubMed ID: 38861479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid nanoparticle-based mRNA candidates elicit potent T cell responses.
    Zeng Y; Escalona-Rayo O; Knol R; Kros A; Slütter B
    Biomater Sci; 2023 Jan; 11(3):964-974. PubMed ID: 36537916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection.
    Takanashi A; Pouton CW; Al-Wassiti H
    Mol Pharm; 2023 Aug; 20(8):3876-3885. PubMed ID: 37491979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemistry of Lipid Nanoparticles for RNA Delivery.
    Eygeris Y; Gupta M; Kim J; Sahay G
    Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2.
    Peng L; Renauer PA; Ökten A; Fang Z; Park JJ; Zhou X; Lin Q; Dong MB; Filler R; Xiong Q; Clark P; Lin C; Wilen CB; Chen S
    Cell Rep Med; 2022 May; 3(5):100634. PubMed ID: 35561673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV
    Valentin A; Bergamaschi C; Rosati M; Angel M; Burns R; Agarwal M; Gergen J; Petsch B; Oostvogels L; Loeliger E; Chew KW; Deeks SG; Mullins JI; Pavlakis GN; Felber BK
    Front Immunol; 2022; 13():945706. PubMed ID: 35935984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria.
    Meulewaeter S; Aernout I; Deprez J; Engelen Y; De Velder M; Franceschini L; Breckpot K; Van Calenbergh S; Asselman C; Boucher K; Impens F; De Smedt SC; Verbeke R; Lentacker I
    J Control Release; 2024 Jun; 370():379-391. PubMed ID: 38697317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.
    Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP
    Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2.
    Zhang Y; Yan J; Hou X; Wang C; Kang DD; Xue Y; Du S; Deng B; McComb DW; Liu SL; Zhong Y; Dong Y
    Nano Lett; 2023 Apr; 23(7):2593-2600. PubMed ID: 36942873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
    Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
    Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNA-LNP vaccination-based immunotherapy augments CD8
    Qiu K; Duan X; Mao M; Song Y; Rao Y; Cheng D; Feng L; Shao X; Jiang C; Huang H; Wang Y; Li H; Chen X; Wu S; Luo D; Chen F; Peng X; Zheng Y; Wang H; Liu J; Zhao Y; Song X; Ren J
    NPJ Vaccines; 2023 Sep; 8(1):144. PubMed ID: 37773254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs.
    Tombácz I; Laczkó D; Shahnawaz H; Muramatsu H; Natesan A; Yadegari A; Papp TE; Alameh MG; Shuvaev V; Mui BL; Tam YK; Muzykantov V; Pardi N; Weissman D; Parhiz H
    Mol Ther; 2021 Nov; 29(11):3293-3304. PubMed ID: 34091054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNAs encoding self-DNA reactive cGAS enhance the immunogenicity of lipid nanoparticle vaccines.
    Zhivaki D; Gosselin EA; Sengupta D; Concepcion H; Arinze C; Chow J; Nikiforov A; Komoroski V; MacFarlane C; Sullivan C; Kagan JC
    mBio; 2023 Dec; 14(6):e0250623. PubMed ID: 37937842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models.
    Maruggi G; Mallett CP; Westerbeck JW; Chen T; Lofano G; Friedrich K; Qu L; Sun JT; McAuliffe J; Kanitkar A; Arrildt KT; Wang KF; McBee I; McCoy D; Terry R; Rowles A; Abrahim MA; Ringenberg MA; Gains MJ; Spickler C; Xie X; Zou J; Shi PY; Dutt T; Henao-Tamayo M; Ragan I; Bowen RA; Johnson R; Nuti S; Luisi K; Ulmer JB; Steff AM; Jalah R; Bertholet S; Stokes AH; Yu D
    Mol Ther; 2022 May; 30(5):1897-1912. PubMed ID: 34990810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-activated IL-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy.
    Jiang Y; Zhang Y; Liu C; Liu J; Xue W; Wang Z; Li X
    J Control Release; 2024 Apr; 368():663-675. PubMed ID: 38492862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Ionizable Lipid Nanoparticles for SARS-CoV-2 Omicron mRNA Delivery.
    Long J; Yu C; Zhang H; Cao Y; Sang Y; Lu H; Zhang Z; Wang X; Wang H; Song G; Yang J; Wang S
    Adv Healthc Mater; 2023 May; 12(13):e2202590. PubMed ID: 36716702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2.
    Mao S; Li S; Zhang Y; Long L; Peng J; Cao Y; Mao JZ; Qi X; Xin Q; San G; Ding J; Jiang J; Bai X; Wang Q; Xu P; Xia H; Lu L; Xie L; Kong D; Zhu S; Xu W
    Nano Today; 2023 Feb; 48():101730. PubMed ID: 36570700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.
    Schoenmaker L; Witzigmann D; Kulkarni JA; Verbeke R; Kersten G; Jiskoot W; Crommelin DJA
    Int J Pharm; 2021 May; 601():120586. PubMed ID: 33839230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.